Fosfotreoniini

Fosfotreoniini is a medication used to treat certain types of cancer, specifically those that have spread to the brain or spinal cord. It is a prodrug, meaning it is converted into its active form, treoniini, in the body. The active form of fosfotreoniini works by inhibiting the growth of cancer cells and reducing the production of certain proteins that are important for cancer cell survival.

Fosfotreoniini is typically administered intravenously (into a vein) over a period of several hours. The dosage and duration of treatment depend on the type and stage of cancer, as well as the patient's overall health and response to treatment. Common side effects of fosfotreoniini may include nausea, vomiting, diarrhea, and fatigue. Serious side effects are rare but can include allergic reactions, low blood pressure, and changes in heart rate.

Fosfotreoniini is not a cure for cancer, but it can help slow the growth of cancer cells and improve symptoms in some patients. It is often used in combination with other cancer treatments, such as chemotherapy or radiation therapy. The effectiveness of fosfotreoniini varies among patients, and its use is typically determined by a healthcare team based on individual patient factors.

Fosfotreoniini was approved for medical use in the United States in 2018. It is available under the brand name Trexall and is manufactured by Amgen Inc. The medication is subject to strict regulations and is only available through a restricted distribution program to ensure it is used appropriately and under the supervision of healthcare professionals.